ArticlePloS one2026
Global profiling of α-glucosidase inhibitors from Citri Reticulatae Pericarpium based on affinity ultrafiltration screening coupled with UPLC-ESI-Orbitrap-MS method.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As a medicinal and edible herb, Citri Reticulatae Pericarpium has multiple biological activities. The latest modern pharmacological researches have found that Citri Reticulatae Pericarpium has the effect of lowering blood sugar, and its extract can inhibit the activity of α-glucosidase. However, which component has inhibitory activity on α-glucosidase and the degree of inhibition are not clear. In order to solve this problem, this study used affinity ultrafiltration screening coupled with UPLC-ESI-Orbitrap-MS method to systematically screen α-glucosidase inhibitors from Citri Reticulatae Pericarpium for the first time. Through affinity ultrafiltration technology, the active components were selected, and through UPLC-ESI-Orbitrap-MS technology, their structures were identified. Finally, total 84 active ingredients were selected as α-glucosidase inhibitors, and most of them were multimethoxy flavonoids. Our results indicated that inhibiting α-glucosidase activity was probably one of the most important mechanisms for Citri Reticulatae Pericarpium exerting its hypoglycemic effect. In addition, our results first reported that multimethoxy flavonoids had the effects of hypoglycemic activity and potential anti-diabetes value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.